Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT00936819
PHASE2

The Enhanced Angiogenic Cell Therapy - Acute Myocardial Infarction Trial

Sponsor: Ottawa Hospital Research Institute

View on ClinicalTrials.gov

Summary

This will be the first clinical trial to include a strategy designed to enhance the function of autologous progenitor cells by overexpressing eNOS, and the first to use combination gene and cell therapy for the treatment of cardiac disease.

Official title: A Phase IIb, Randomized, Double-blind, Placebo Controlled Study Using Transplantation of Autologous Early Endothelial Progenitor Cells(EPCs) for Patients Who Have Suffered Acute Myocardial Infarction

Key Details

Gender

All

Age Range

18 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

47

Start Date

2013-07-19

Completion Date

2029-11

Last Updated

2025-08-15

Healthy Volunteers

No

Interventions

BIOLOGICAL

Plasma-Lyte A and 25% Autologous Plasma

Single dose of 8 mls given by investigator via intracoronary injection into stent of infarct-related artery

BIOLOGICAL

Autologous EPCs

Single dose of 20 million cells in 8 mls given by investigator via intracoronary injection into stent of infarct-related artery

BIOLOGICAL

Autologous EPCs Transfected with human eNOS

Single dose of 20 million cells in 8 mls given by investigator via intracoronary injection into stent of infarct-related artery

Locations (3)

University of Ottawa Heart Institute

Ottawa, Ontario, Canada

St. Michael's Hospital

Toronto, Ontario, Canada

L'institut de cardiologie de Montreal

Montreal, Quebec, Canada